ClinVar Miner

Submissions for variant NM_000518.4(HBB):c.410G>A (p.Gly137Asp) (rs33949486)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000016385 SCV000603900 likely benign not specified 2018-09-25 criteria provided, single submitter clinical testing The Hb Hope variant (HBB c.410G>A; p.Gly137Asp, also known as Gly136Asp when numbered from the mature protein; rs33949486) has been reported in numerous individuals, either found as a heterozygote (Minnich 1965) or in combination with other pathogenic variants (Ingle 2004, Cook 2013, HbVar and references therein). Although this hemoglobin variant is mildly unstable, has reduced oxygen affinity (Minnich 1965), and has been reported to interfere with measurements of HbA1c levels (Chakraborty 2015), it has not been associated with significant clinical phenotypes when found in combination with Hb S/C/E or beta thalassemia traits (Ingle 2004, Cook 2013). The variant is reported as benign/likely benign by multiple laboratories in ClinVar (Variation ID: 15202) and is found in the general population with an overall allele frequency of 0.001% (3/251372 alleles) in the Genome Aggregation Database. However, based on available information, the Hb Hope variant is considered to be likely benign. References: Link to HbVar database for Hb Hope: http://globin.bx.psu.edu/cgi-bin/hbvar/query_vars3?mode=output&display_format=page&i=548 Chakraborty S et al. Interference of the Hope Hemoglobin With Hemoglobin A1c Results. Lab Med. 2015 Summer;46(3):221-5. Cook C et al. The clinical and laboratory spectrum of Hb C [beta6(A3)Glu?Lys, GAG>AAG] disease. Hemoglobin. 2013;37(1):16-25. Ingle J et al. Hb Hope [beta136(H14)Gly-->Asp (GGT-->GAT)]: interactions with Hb S [beta6(A3)Glu-->Val (GAG-->GTG)], other variant hemoglobins and thalassemia. Hemoglobin. 2004; 28(4):277-85. Minnich V et al. Hemoglobin Hope: A beta chain variant. Blood. 1965;25:830-8.
Integrated Genetics/Laboratory Corporation of America RCV000016385 SCV000697131 likely benign not specified 2019-08-02 criteria provided, single submitter clinical testing Variant summary: HBB c.410G>A (p.Gly137Asp) results in a non-conservative amino acid change located in the Globin domain (IPR000971) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 251372 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.410G>A has been widely reported in the literature as a clinically innocuous variant in individuals with mildly anemic phenotypes and also in co-occurrence among individuals with HbCS, Hb-H disease, and HbE/beta-thallasemia (Minnich_1965, Ingle_2004, Enoki_1989, Martinez_1984, Pagnier_1978, Sura_2007, Beneitez_2006, Fucharoen_2012, Svasti_2001, Chunpanich_2004, Rahbar_1992, Pillers_1992, Delacour_2016, Srivorakun_2014). In particular, compound heterozygous individuals with Hb-Hope-HbS genotypes did not present with sickle cell disease phenotype (Ingle_2004). These data indicate that the variant is not strongly associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function (Enoki_1989). The most pronounced variant effect results in reduced oxygen affinity. One clinical diagnostic laboratory and OMIM have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All submitters classified the variant as benign/likely benign. Based on the evidence outlined above, the variant was classified as likely benign.
Mendelics RCV000029996 SCV001138214 benign beta Thalassemia 2019-05-28 criteria provided, single submitter clinical testing
Baylor Genetics RCV001004558 SCV001163640 pathogenic Hb SS disease criteria provided, single submitter clinical testing
OMIM RCV000016385 SCV000036653 benign not specified 2017-12-12 no assertion criteria provided literature only
Integrated Genetics/Laboratory Corporation of America RCV000029996 SCV000052651 likely benign beta Thalassemia 2015-10-02 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.